Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.92 USD
-0.05 (-4.71%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.92 +0.01 (0.55%) 4:28 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 41 - 60 ( 326 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recruitment Reopened for AFFINE Trial of SB-525/HemA; Dosing Expected in Oct
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Ph1/2 Update at SSIEM for ST-920/Fabry; Additional Data in H2:22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Best-in-Class Fabry Program Continues to Shine With Next Update Expected Later This Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Fabry Update at SSIEM; EC Grants TX200 OMPD; Continued Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Frontrunning Fabry GTx Development; Assuming at NEUTRAL, $5 PT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Best-in-Class Fabry Program Nearing Phase 3; Hem-A Clinical Hold Lifted; CAR Treg Program Advancing
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1: FDA Lifts Clinical Hold on AFFINE Trial for SB-525/HemA; Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Pipeline Progressing; Potential Positive Events on Fabry, Hem-A, and CAR Treg Programs on Track in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY21: Continued Pipeline Progress, Fabry Update in H2:22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ST-920''s Differentiated Profile in Fabry Emerges from Ph1/2 STAAR WORLD Update
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BIVV003 SCD Program Comes Home; Fabry Competitors Strengthen ST-920 Program
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data Updates From Key Partnered Programs in Hem-A and Sickle Cell Disease at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021: Updates from Phase 1/2 SCD and SB-525/HemA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L